25I-NBOMe vs Psilocybin
A side-by-side research comparison of 25I-NBOMe and Psilocybin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | 25I-NBOMe | Psilocybin |
|---|---|---|
| Full name | 2C-I-NBOMe (N-bomb) | Psilocybin (from psilocybin mushrooms) |
| Category | Psychedelics | Psychedelics |
| Status | Schedule I (high-risk research compound) | Schedule I (FDA Breakthrough Therapy for depression) |
| Mechanism | A very strong serotonin 5-HT2A receptor agonist active at sub-milligram doses. | Converted in the body to psilocin, which activates serotonin 5-HT2A receptors in the brain. This temporarily loosens rigid thinking patterns and increases connectivity between brain networks. |
| Molecular weight | 427.33 g/mol | 284.25 g/mol |
| Half-life | Short-moderate | ~2-3 hours (psilocin) |
| Bioavailability | Oral | Oral |
| Typical dose | Varies by individual and setting | 10-30 mg in clinical trials |
| Frequency | Occasional | One to a few supervised sessions |
| Route | Sublingual (must not be swallowed) | Oral, in a supervised therapeutic setting |
25I-NBOMe reported benefits
- Listed for awareness and harm reduction
- Often mis-sold as LSD (know the difference)
- NBOMe research compound
Psilocybin reported benefits
- Studied for treatment-resistant depression
- Eases anxiety in life-threatening illness
- Explored for alcohol and tobacco addiction
- Often produces durable improvements after few doses
Related comparisons
Research and educational reference only. Not medical advice.